-
公开(公告)号：MXPA01013440A
公开(公告)日：2003-09-04
申请号：MXPA01013440
申请日：2001-06-05
Applicant: CELLTECH R&D LTD
Inventor： DAVID JOHN KING
-
公开(公告)号：GB0316912D0
公开(公告)日：2003-08-20
申请号：GB0316912
申请日：2003-07-18
Applicant: OXFORD INSTR SUPERCONDUCTIVITY , CELLTECH R&D LTD
Abstract: Magnetic particles are used in therapeutic applications to disrupt a biological material. The particles have intrinsic magnetization, said magnetization being stabilised by inherent magneto-crystal line anisotropy and/or by shape anisotropy. By applying a magnetic field, the magnetic particles are induced to rotate when localised at the target biological material, thereby disrupting the material.
-
-
-
-
Patent Agency Ranking
公开(公告)号：CA2466629A1
公开(公告)日：2003-06-12
申请号：CA2466629
申请日：2002-12-05
Applicant: CELLTECH R&D LTD
Inventor： POPPLEWELL ANDREW GEORGE
IPC: C12N15/09 , C07K16/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/72 , C12P21/08 , C07K16/24 , C12N15/70
Abstract: The present invention relates to a method of production of antibodies wherei n the heavy and light chains of a particular antibody molecule are encoded by the DNA present in a dicistronic message in which the two cistrons are linke d by an optimised intergenic sequence.
-
公开(公告)号：DE69721564D1
公开(公告)日：2003-06-05
申请号：DE69721564
申请日：1997-12-10
Applicant: CELLTECH R&D LTD
Inventor： KING JOHN , CHAPMAN PAUL
-
公开(公告)号：CA2458464A1
公开(公告)日：2003-04-17
申请号：CA2458464
申请日：2002-10-10
Applicant: CELLTECH R&D LTD
Inventor： TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , POPPLEWELL ANDREW GEORGE , MORRISON ROBERT KENDALL
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , A61K47/30 , C12N15/70
Abstract: There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicat ed.
-
公开(公告)号：CA2456291A1
公开(公告)日：2003-02-20
申请号：CA2456291
申请日：2002-08-07
Applicant: CELLTECH R&D LTD
Inventor： DYKE HAZEL JOAN , WATSON ROBERT JOHN
IPC: A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12 , C07D309/08 , A61K31/445
Abstract: A compound of formula (I) wherein : R1 and R2, which may be the same or different, is each a hydrogen atom or a CF3, CF2H or CFH2 group, provided th at when one of R1 or R2 is a hydrogen atom the other is a CF3, CF2H or CFH2 gro up ; and the salts, solvates or hydrates thereof. The compounds are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. The compounds may be expected to be of use in medicine, especially where the avoidance of side effects such as joint pain is desired.
-
-
-
-
-
-
-
-
-
Search Results
485
records
(took 0.023 seconds)
